Cargando…
Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study
BACKGROUND: The rise of drug-resistant tuberculosis (DR-TB) has presented a substantial challenge to the national tuberculosis (TB) control program. Understanding the epidemiology of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) could help clinicians to adapt MDR-TB treatment regimens at...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513164/ https://www.ncbi.nlm.nih.gov/pubmed/36176268 http://dx.doi.org/10.1016/j.ijregi.2022.08.012 |
_version_ | 1784797996267864064 |
---|---|
author | Diriba, Getu Alemu, Ayinalem Tola, Habteyes Hailu Yenew, Bazezew Amare, Misikir Eshetu, Kirubel Sinshaw, Waganeh Abebaw, Yeshiwork Meaza, Abyot Seid, Getachew Moga, Shewki Zerihun, Betselot Getu, Melak Dagne, Biniyam Mollalign, Hilina Tadesse, Mengistu Buta, Bedo Wordofa, Niguse Alemu, Ephrem Erresso, Ashenafi Hailu, Michael Tefera, Zigba Wondimu, Amanuel Belhu, Tegegn Gamtesa, Dinka Fekadu Getahun, Muluwork Kebede, Abebaw Abdela, Saro |
author_facet | Diriba, Getu Alemu, Ayinalem Tola, Habteyes Hailu Yenew, Bazezew Amare, Misikir Eshetu, Kirubel Sinshaw, Waganeh Abebaw, Yeshiwork Meaza, Abyot Seid, Getachew Moga, Shewki Zerihun, Betselot Getu, Melak Dagne, Biniyam Mollalign, Hilina Tadesse, Mengistu Buta, Bedo Wordofa, Niguse Alemu, Ephrem Erresso, Ashenafi Hailu, Michael Tefera, Zigba Wondimu, Amanuel Belhu, Tegegn Gamtesa, Dinka Fekadu Getahun, Muluwork Kebede, Abebaw Abdela, Saro |
author_sort | Diriba, Getu |
collection | PubMed |
description | BACKGROUND: The rise of drug-resistant tuberculosis (DR-TB) has presented a substantial challenge to the national tuberculosis (TB) control program. Understanding the epidemiology of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) could help clinicians to adapt MDR-TB treatment regimens at an earlier stage. This study aimed to assess second-line anti-TB drug resistance among MDR-TB patients in Ethiopia using routine laboratory-based data. METHODS: Laboratory-based cross-sectional data were collected from the national TB reference laboratory and seven regional tuberculosis culture laboratories in Ethiopia from July 2019 to March 2022. The required data, such as drug-susceptibility testing (DST) results and sociodemographics, were collected on a structured checklist from laboratory registration books and electronic databases. Data were entered into a Microsoft Excel spreadsheet and analyzed using SPSS version 23. Descriptive statistics were performed to show the distribution and magnitude of drug resistance. RESULTS: Second-line drugs (SLDs) susceptibility testing was performed for 644 MDR isolates, of which 19 (3%) were found to be pre-XDR-TB cases. Of the total MDR-TB isolates, 19 (3%) were resistant to at least one fluoroquinolone drug, while 11 (1.7%) were resistant to at least one injectable second-line drug. Of the 644 MDR-TB isolates, 1.9% (5/261) pre-XDR were from new MDR-TB cases, while 3.7% (14/383) were from previously treated MDR-TB patients. The most frequently identified mutations, based on MTBDRsl results, were in codon A90V of the gyrA gene (77.3%) and A1401G of the rrs gene (45.5%). CONCLUSION: The overall prevalence of pre-XDR-TB in Ethiopia is considerable. The majority of SLD resistance mutations were in the gyrA gene at position A90V. Modern, rapid DST is necessary to enable identification of pre-XDR-TB and XDR-TB in supporting proper regimen administration for patients. |
format | Online Article Text |
id | pubmed-9513164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-95131642022-09-28 Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study Diriba, Getu Alemu, Ayinalem Tola, Habteyes Hailu Yenew, Bazezew Amare, Misikir Eshetu, Kirubel Sinshaw, Waganeh Abebaw, Yeshiwork Meaza, Abyot Seid, Getachew Moga, Shewki Zerihun, Betselot Getu, Melak Dagne, Biniyam Mollalign, Hilina Tadesse, Mengistu Buta, Bedo Wordofa, Niguse Alemu, Ephrem Erresso, Ashenafi Hailu, Michael Tefera, Zigba Wondimu, Amanuel Belhu, Tegegn Gamtesa, Dinka Fekadu Getahun, Muluwork Kebede, Abebaw Abdela, Saro IJID Reg Title Page BACKGROUND: The rise of drug-resistant tuberculosis (DR-TB) has presented a substantial challenge to the national tuberculosis (TB) control program. Understanding the epidemiology of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) could help clinicians to adapt MDR-TB treatment regimens at an earlier stage. This study aimed to assess second-line anti-TB drug resistance among MDR-TB patients in Ethiopia using routine laboratory-based data. METHODS: Laboratory-based cross-sectional data were collected from the national TB reference laboratory and seven regional tuberculosis culture laboratories in Ethiopia from July 2019 to March 2022. The required data, such as drug-susceptibility testing (DST) results and sociodemographics, were collected on a structured checklist from laboratory registration books and electronic databases. Data were entered into a Microsoft Excel spreadsheet and analyzed using SPSS version 23. Descriptive statistics were performed to show the distribution and magnitude of drug resistance. RESULTS: Second-line drugs (SLDs) susceptibility testing was performed for 644 MDR isolates, of which 19 (3%) were found to be pre-XDR-TB cases. Of the total MDR-TB isolates, 19 (3%) were resistant to at least one fluoroquinolone drug, while 11 (1.7%) were resistant to at least one injectable second-line drug. Of the 644 MDR-TB isolates, 1.9% (5/261) pre-XDR were from new MDR-TB cases, while 3.7% (14/383) were from previously treated MDR-TB patients. The most frequently identified mutations, based on MTBDRsl results, were in codon A90V of the gyrA gene (77.3%) and A1401G of the rrs gene (45.5%). CONCLUSION: The overall prevalence of pre-XDR-TB in Ethiopia is considerable. The majority of SLD resistance mutations were in the gyrA gene at position A90V. Modern, rapid DST is necessary to enable identification of pre-XDR-TB and XDR-TB in supporting proper regimen administration for patients. Elsevier 2022-08-30 /pmc/articles/PMC9513164/ /pubmed/36176268 http://dx.doi.org/10.1016/j.ijregi.2022.08.012 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Title Page Diriba, Getu Alemu, Ayinalem Tola, Habteyes Hailu Yenew, Bazezew Amare, Misikir Eshetu, Kirubel Sinshaw, Waganeh Abebaw, Yeshiwork Meaza, Abyot Seid, Getachew Moga, Shewki Zerihun, Betselot Getu, Melak Dagne, Biniyam Mollalign, Hilina Tadesse, Mengistu Buta, Bedo Wordofa, Niguse Alemu, Ephrem Erresso, Ashenafi Hailu, Michael Tefera, Zigba Wondimu, Amanuel Belhu, Tegegn Gamtesa, Dinka Fekadu Getahun, Muluwork Kebede, Abebaw Abdela, Saro Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study |
title | Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study |
title_full | Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study |
title_fullStr | Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study |
title_full_unstemmed | Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study |
title_short | Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study |
title_sort | pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in ethiopia: a laboratory-based surveillance study |
topic | Title Page |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513164/ https://www.ncbi.nlm.nih.gov/pubmed/36176268 http://dx.doi.org/10.1016/j.ijregi.2022.08.012 |
work_keys_str_mv | AT diribagetu preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT alemuayinalem preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT tolahabteyeshailu preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT yenewbazezew preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT amaremisikir preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT eshetukirubel preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT sinshawwaganeh preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT abebawyeshiwork preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT meazaabyot preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT seidgetachew preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT mogashewki preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT zerihunbetselot preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT getumelak preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT dagnebiniyam preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT mollalignhilina preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT tadessemengistu preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT butabedo preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT wordofaniguse preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT alemuephrem preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT erressoashenafi preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT hailumichael preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT teferazigba preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT wondimuamanuel preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT belhutegegn preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT gamtesadinkafekadu preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT getahunmuluwork preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT kebedeabebaw preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy AT abdelasaro preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy |